
    
      Patients will receive a single intratumor injection of NBTXR3 on day 1 and will receive
      external beam radiotherapy starting on day 2 up to completion of 5 weeks, 5 days a week of
      treatment (50Gy, 2Gy/fraction). Then, all patients will undergo surgical resection of the
      tumor 5 weeks later and will be followed for wound healing and toxicity assessment. A visit
      of end of treatment will take place approximately 3-4 weeks after surgery. Patients will be
      followed for evaluation of their disease status and adverse events every 8 weeks until the
      end of study.
    
  